Pharmaceuticals

Revenue of the Preventive Vaccines Market Predicted to Achieve $131.27 Billion by 2030, Driven by 9.8% CAGR

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the preventive vaccines market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Preventive Vaccines Market’s size between 2026 and 2030?

The preventive vaccines market has shown substantial growth in recent years. It is anticipated to increase from $83 billion in 2025 to $90.33 billion in 2026, progressing at a compound annual growth rate (CAGR) of 8.8%. This historical expansion can be linked to the successful eradication and management of infectious diseases, governmental vaccination efforts, heightened public health awareness, the creation of global immunization schemes, and increased financial contributions from international health bodies.

The preventive vaccines market is anticipated to experience robust expansion in the coming years. Projections indicate it will reach $131.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. This expansion during the forecast period is primarily driven by factors such as the advancement of next-generation vaccine platforms, the increasing global population and urbanization, heightened initiatives for outbreak preparedness, the broadening of adult immunization programs, and the growth of public–private collaborations in vaccine development. Key trends expected over the same period encompass the broadening of national immunization programs, a growing emphasis on preventive healthcare and disease control, an escalating demand for both pediatric and geriatric vaccinations, the development of more combination and multivalent vaccines, and the reinforcement of cold chain and vaccine storage infrastructure.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Which Drivers Are Shaping Strategic Decisions In The Preventive Vaccines Market?

The future expansion of the preventive vaccines market is anticipated to be significantly driven by the rising occurrence of infectious diseases. These illnesses are characterized by their origin in pathogenic microorganisms like bacteria, viruses, fungi, or parasites, capable of spreading between individuals or via environmental vectors. Factors such as growing urbanization, international travel, and antimicrobial resistance contribute to the heightened prevalence of infectious diseases, making their spread quicker and control more challenging. Preventive vaccines play a crucial role in managing these diseases by activating the immune system to identify and combat pathogens prior to infection, thus lowering both the incidence and transmission rates. As an illustration, in 2024, the World Health Organization, an intergovernmental organization located in Switzerland, disclosed that global new diagnoses of TB (tuberculosis) cases hit 8.2 million in 2023, up from 7.5 million in 2022. Consequently, the increasing frequency of infectious diseases is a primary catalyst for the growth observed in the preventive vaccines market.

What Segment Classifications Make Up The Preventive Vaccines Market?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

Which Market Trends Are Opening Growth Opportunities In The Preventive Vaccines Market?

Leading companies within the preventive vaccines market are directing their efforts towards breakthroughs in vaccine technology, including sophisticated mRNA technology platforms. This focus aims to boost vaccine effectiveness, refine safety aspects, accelerate development and manufacturing processes, and offer more extensive protection against novel variants of infectious diseases. These advanced mRNA technology platforms represent innovative approaches that utilize messenger RNA to guide cells in creating particular proteins, thereby stimulating a precise immune response. As an illustration, in March 2025, Moderna Inc., a US-based biotechnology firm, declared that its new COVID-19 vaccine, mRNA-1283 (mNEXSPIKE), received FDA approval. This vaccine is approved for adults aged 65 and older, as well as for individuals aged 12–64 who possess one or more risk factors as defined by the CDC. The introduction of mNEXSPIKE signifies a major leap forward in next-generation mRNA vaccine technology, providing enhanced stability and simpler storage requirements when contrasted with preceding iterations. This progression is anticipated to boost vaccine accessibility and distribution, especially benefiting underserved and remote communities.

Which Leading Companies Dominate The Preventive Vaccines Market Share?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

How Does The Preventive Vaccines Market Perform Across Major Global Regions?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Preventive Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24667&type=smp

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2026, By The Business Research Company

Adult Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Travel Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795